Tamoxifen monitoring studies in breast cancer patients by micellar liquid chromatography

Esteve-Romero, Josep; Ochoa-Aranda, Enrique; Bose, Devasish; Rambla-Alegre, Maria; Peris-Vicente, Juan; Martinavarro-Domínguez, Adrià
June 2010
Analytical & Bioanalytical Chemistry;Jun2010, Vol. 397 Issue 4, p1557
Academic Journal
A simple micellar liquid chromatographic procedure is described to determine tamoxifen in plasma. To perform the analysis, tamoxifen solutions were diluted in water and UV-irradiated for 20 min to form the photocycled derivative with a phenanthrene core which shows intense fluorescence. Samples were then directly injected, thus avoiding long extraction and experimental procedures. The resolution from the matrix was performed with a mobile phase containing 0.15 M SDS–7% n-butanol at pH 3 running at 1.5 mL/min through a C18 column at 40 °C. Detection was carried out by fluorescence, and the excitation and emission wavelengths were 260 and 380 nm, respectively. The chromatographic analysis time was less than 15 min. The analytical methodology was validated following the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines. The response of the drug in plasma was linear and in the 0.5–15 µg/mL range, with r2 > 0.999. Accuracy and precision were <9% in both cases. The limits of detection and quantification (in nanograms per millilitre) were 50 and 150 in plasma, respectively. The method developed herein shows no interferences by endogenous compounds. Finally, the analytical method was used to determine the amount of tamoxifen in the plasma of several breast cancer patients from a local hospital.


Related Articles

  • Biologic Activity of Tamoxifen at Low Doses in Healthy Women. Decensi, Andrea; Bonanni, Bernardo // JNCI: Journal of the National Cancer Institute;10/07/98, Vol. 90 Issue 19, p1461 

    Presents the results of a clinical trial completed in the United States which indicated that the drug Tamoxifen administered to women at risk can reduce breast cancer incidence by approximately 50%. Risk factors of the drug; Examination of the effects of Tamoxifen on several biomarkers, given...

  • Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology. Dahmane, Elyes; Boccard, Julien; Csajka, Chantal; Rudaz, Serge; Décosterd, Laurent; Genin, Eric; Duretz, Bénédicte; Bromirski, Maciej; Zaman, Khalil; Testa, Bernard; Rochat, Bertrand // Analytical & Bioanalytical Chemistry;Apr2014, Vol. 406 Issue 11, p2627 

    Liquid-chromatography (LC) high-resolution (HR) mass spectrometry (MS) analysis can record HR full scans, a technique of detection that shows comparable selectivity and sensitivity to ion transitions (SRM) performed with triple-quadrupole (TQ)-MS but that allows de facto determination of 'all'...

  • A high performance liquid chromatographic assay of Mefloquine in saliva after a single oral dose in healthy adult Africans.  // Malaria Journal;2012, Vol. 11 Issue 1, p59 

    The article presents findings of a research conducted on examining a non-invasive method for assay of mefloquine in saliva. It mentions that mefloquine-artesunate is a formulation of artemisinin based combination therapy (ACT), as recommended by the World Health Organization (WHO). It concludes...

  • Tamoxifen/paroxetine/citalopram interaction.  // Reactions Weekly;10/22/2011, Issue 1374, p33 

    The article describes the case of a 47-year-old woman with breast cancer who developed hot flashes and a major depressive episode after receiving tamoxifen given before a surgery.

  • `I got breast cancer at 24.'. Brody, Liz // Glamour;Jul99, Vol. 97 Issue 7, p182 

    Part I. Presents a story of Julie Brier, who suffered from breast cancer at 24. How her disease affects her life; Reason doctors fail to catch breast cancer in young women; How a doctor should proceed if a women walk in a breast lump; Her chemotherapy; Side effects of taking tamoxifen as a...

  • FDA committee recommends cancer drugs. Levy, Sandra // Drug Topics;9/21/98, Vol. 142 Issue 18, p22 

    States that the United States Food and Drug Administration's oncologic drugs advisory committee recommended the approval for several drugs used in the treatment of patients with breast cancer. Identification of the drugs; In-depth look at the tamoxifen drug; Comments from Rowena Schwartz,...

  • SOUND OFF. Morreale, Elena // Original Internist;Sep2014, Vol. 21 Issue 3, p117 

    The article provides information on tamoxifen, a drug recommended for recovering breast cancer patients. Topics discussed include the therapeutic function of tamoxifen as a selective estrogen receptor modulator (SERM), the side effects of tamoxifen such as nausea, eye damage and blood clots, and...

  • Correction: Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients. null, null // PLoS ONE;10/23/2015, Vol. 10 Issue 10, p1 

    No abstract available.

  • Atypical Fatigue. Sharp, Kathy // Clinical Journal of Oncology Nursing;Oct2007, Vol. 11 Issue 5, p628 

    Case Study: Mrs. S is a 63-year-old retired teacher who returns to the office for breast cancer follow-up. She was diagnosed with intraductal carcinoma, and her treatment included a modified radial mastectomy followed by four cycles of doxorubicin and cyclosphosphamide. Her tumor was estrogen...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics